Ep 1: Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
In this episode of the Radcliffe Cardiology Podcast, Dr Otilia Tica (University of Medicine of Oradea, Oradea, RO) is joined by Patient Representative, Mary Stanbury to outline ways in which cardiologists can break the cycle of heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF). This discussion is centered around a recently published article authored by Dr Tica in CFR Journal, 'Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation'. [https://www.cfrjournal.com/articles/breaking-cycle-heart-failure-preserved-ejection-fraction-and-atrial-fibrillation]
In this episode, key discussion topics include: - Diagnosis, treatment and patient wellbeing for comorbid HFpEF and AF - Adverse event rates and prognostic implications for HFpEF and AF, and how we can close the gaps in the diagnostic challenges - Approaches and critical steps to patient management.
Prefer to watch in video format? Click here.
If you have any questions or suggestions, please email managingeditor@ecrjournal.com.
Read MoreRead Less
In this episode of "View from the Thoraxcenter," Prof Nicolas Van Mieghem and Dr Joost Daemen preview the most anticipated late-breaking and featured science trials of ACC.23 and discuss their potential impact on patient care and research.
Read More
All Episodes
In this episode of the Innovations in Cardiology series, host Dr Dipti Itchhaporia is joined by Dr Alexander Van Rosendael to discuss the findings from the CONFIRM2 trial.
Read More
Explore the cardiovascular breakthroughs shaping AHA 2024!
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
Read More
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
Dr Dipti Itchhaporia, former president of the ACC, is joined by Dr C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024.
Read More
Host, Dr Dipti Itchhaporia is joined by PI, Dr Derek Chew to discuss the findings from the RAPIDxAI trial, which aims to improve the assessment of suspected cardiac chest pain in emergency departments (ED) using a machine-learning algorithm that will interpret high-sensitivity troponin test results, assisting the diagnosis of myocardial infarction (MI) and other myocardial injuries.
Read More
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia welcomes two leading experts in artificial intelligence in cardiology: Dr David Ouyang from Cedars-Sinai Medical Center in Los Angeles, and Dr Francisco Lopez-Jiminez from the Mayo Clinic in Rochester, MN.
Read More
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC's Thoraxcenter for an insightful preview of the late-breaking science data to look out for at the 2024 EuroPCR meeting.
Read More
Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24.
Read More
What’s hot at ACC.24?
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
Read More
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
In this episode of the Radcliffe Podcast, we are joined by Dr Raymond Pranata, Dr Mohammad Iqbal and Dr Giky Karwiky (Hasan Sadikin General Hospital, Bandung, Indonesia) as they discuss their recently published systematic review and meta-analysis of very-high-power short-duration ablation as compared to conventional ablation for the treatment of pulmonary vein isolation in atrial fibrillation.
Read More
Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023.
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Read More
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.
Inflammation and Atherosclerosis – What is the Link with CKD? Join Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Lina Badimon (Hospital of Santa Creu and San Pau, Barcelona, Spain) as they discuss that very question.
Read More
Prof Juan Carlos Kaski (St George’s University of London, UK) alongside Dr Peter Libby (Brigham and Women’s Hospital, Boston, US) provide us with a short and concise discussion regarding Therapeutic Targets and Mode of Action.
Read More
Inflammatory Signalling in Atherosclerosis and CKD is the topic of interest in this short peer to peer discussion involving Prof Juan Carlos Kaski (St George’s University of London, UK) and Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US).
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Read More
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Prof Juan Carlos Kaski (St George’s University of London, UK) is joined by Prof Paul Ridker (Brigham and Women’s Hospital, Boston, US) to discuss Unmet Clinical Needs in Atherosclerosis and Chronic Kidney Disease where they cover topics such as elevated hsCRP and chronic kidney disease.
Read More
Prof Jean-Claude Tardif (Montreal Heart Institute, Canada) gives us a comprehensive overview of the COLCOT trial.
Read More